Frontiers in Clinical Drug Research - Anti-Cancer Agents

Volume 2

by

Atta-ur-Rahman

DOI: 10.2174/97816810807271150201
eISBN: 978-1-68108-072-7, 2015
ISBN: 978-1-68108-073-4
ISSN: 2451-8905 (Print)
ISSN: 2215-0803 (Online)



Recommend this eBook to your Library



Frontiers in Clinical Drug Research - Anti-Cancer Agents should prove to be a valuable resource for pharmaceutical sc...[view complete introduction]

Table of Contents

Preface

- Pp. i-ii (2)

Atta-ur-Rahman

Download Free

List of Contributors

- Pp. iii-iv (2)

Atta-ur-Rahman

Download Free

Dendrimers for Drug Delivery of Anticancer Drugs

- Pp. 3-25 (23)

Ugir Hossain Sk and Chie Kojima

View Abstract Purchase Chapter

An Overview of Cytotoxic Chemotherapy, Immunotherapy, and Targeted Therapy for Advanced Cutaneous Squamous Cell Carcinoma

- Pp. 26-49 (24)

Yasuhiro Nakamura, Yukiko Teramoto, Sayuri Sato and Akifumi Yamamoto

View Abstract Purchase Chapter

Bayesian Systems for Optimizing Treatment Protocols in Oncology

- Pp. 50-119 (70)

Robert C. Jackson, Eric Fernandez and Tomas Radivoyevitch

View Abstract Purchase Chapter

Molecular Approaches to Target Heat Shock Proteins for Cancer Treatment

- Pp. 120-164 (45)

Daniel R. Ciocca, Francesco Cappello, F. Darío Cuello-Carrión and André- Patrick Arrigo

View Abstract Purchase Chapter

Targeting the Inhibitor of Apoptosis Proteins with Small Molecules: Recent Advances and Clinical Challenges

- Pp. 165-208 (44)

Kinsie Arnst and Wei Li

View Abstract Purchase Chapter

Some Natural Products May Represent a Future Alternative to Anti-Neoplastic Medicine

- Pp. 209-229 (21)

Glenda Nicioli da Silva and Daisy Maria Fávero Salvadori

View Abstract Purchase Chapter

Chemical Control of Cancer: The Best Way Forward

- Pp. 230-261 (32)

Doug Dix

View Abstract Download Free

Subject Index

- Pp. 262-263 (2)

Atta-ur-Rahman

Download Free

Preface

The present volume of Frontiers in Clinical Drug Research - Anti-Cancer Agents presents cutting edge reviews on developments in new and more powerful agents against cancer.

The advantages that dendrimers offer as drug carriers are associated with their unique structure that imparts inner space and multiple terminal groups for drug encapsulation and conjugation. Hossain Sk and Kojima discuss the use of dendrimers as drug delivery vehicles for anticancer drugs.

Cutaneous squamous cell carcinoma (SCC) is the second most common type of nonmelanoma skin cancer after basal cell carcinoma, and its incidence is on the rise. In Chapter 2, Nakamura et al. highlighted the importance of cytotoxic chemotherapy, immunotherapy and targeted therapy for advanced cutaneous squamous cell carcinoma. This review describes the previously published clinical trials for assessing the potency and efficacy of various approaches used for treating advanced cutaneous SCC. It provides the current evidence-based approaches and highlights the areas for further research.

In Chapter 3, Jackson et al. discuss important developments in the field of pharmacodynamic biomarkers that have greatly enhanced the information obtainable from clinical trials and played a vital role in the development of pharmacokinetic/pharmacodynamic (PK-PD) models. The literature on the use of Bayesian systems in oncology (involving prior assumptions being made based on preclinical data and historical precedent) is reviewed. The applications of these models to develop strategies for new drugs, and to develop personalised medicine approaches in oncology are discussed.

In Chapter 4, Ciocca et al. discussed the molecular approaches for targeting the Heat Shock proteins for cancer treatment. They discuss HSP90, HSP27, HSP70, and HSP60 as targets for anticancer therapy.

A promising strategy to block inhibitors of apoptosis (IAP) proteins IAPs is with smallmolecule IAP antagonists. A number of small molecule inhibitors have been developed that have the potential to bring exciting new treatment options to overcome apoptotic resistance for anticancer treatment. In chapter 5, Arnst and Li have presented the recent advances and clinical challenges of targeting the inhibitor of proteins with some of the recently developed small molecule IAP antagonists. They have highlighted the biological mechanisms of IAPs and provided an update to the clinical challenges, recent advances and potential opportunities for small-molecule IAP inhibitors.

Many substances present in fruits, vegetables and herbal essential oils have been shown to have important antiproliferative activity, inducing cell and genomic changes favorable for cancer prevention and therapy. In Chapter 6, da Silva and Salvadori highlight the importance of natural products as anti-neoplastic medicines. They stress that products that have natural origin are found to be more compatible with the human body and associated with fewer side effects.

In the final chapter contributed by Doug Dix, the chemotherapy and chemotherapeutic paradigms are discussed in the light of modern challenges. The chapter describes the ways for overcoming tumor defenses, preventing treatment resistance, as well as how to preserve and enhance the host anti-cancer responses and lessen the severe side effects.

I hope that the current volume of this popular Series will provide fresh insights into development of recent approaches to anti-cancer therapy for interested researchers and pharmaceutical scientists. I would like to thank the editorial staff, particularly Mr. Mahmood Alam (Director Publication) and Mr. Shehzad Naqvi (Senior Manager Publication) for their hard work and determined efforts.

Atta-ur-Rahman, FRS
Kings College
University of Cambridge
Cambridge
UK

List of Contributors

Editor(s):
Atta-ur-Rahman FRS
Kings College, University of Cambridge
Honorary Life Fellow
Cambridge
UK




Contributor(s):
Akifumi Yamamoto
Department of Skin Oncology/Dermatology, Comprehensive Cancer Center
Saitama Medical University International Medical Center
Saitama
Japan


André-Patrick Arrigo
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic
Sun Yat-sen University
54 Xianlie South Road, Guangzhou
Guangdong, 510060
China
/
Apoptosis, Cancer and Development Laboratory, Lyon Cancer Research Center
INSERM U1052-CNRS UMR5286, Claude Bernard University Lyon 1
54 Xianlie South Road, Guangzhou
Lyon
France


Chie Kojima
Department of Applied Chemistry, Graduate School of Engineering
Prefecture University, 1-2 Gakuen-cho, Naka-ku, Sakai
Osaka, 599-8570
Japan


Daisy Maria Fávero Salvadori
Departamento de Patologia – Faculdade de Medicina de Botucatu
Universidade Estadual Paulista – UNESP
Botucatu
SP
Brazil


Daniel R. Ciocca
Laboratory of Oncology
Institute of Experimental Medicine and Biology of Cuyo (IMBECU), Technology and Scientific Center (CCT)-National Research Council of Argentina (CONICET)
Luzhou Medical College
Mendoza
Argentina


Doug Dix
Department of Health Science
University of Hartford West Hartford
CT, 06117
U.S.A


Eric Fernandez
Physiomics plc
Oxford
UK


Francesco Cappello
Department of Experimental Biomedicine and Clinical Neurosciences
University of Palermo
Palermo
Italy
/
Euro-Mediterranean, nstitute of Science and Technology
Palermo
Italy


F. Darío Cuello-Carrión
Laboratory of Oncology
Institute of Experimental Medicine and Biology of Cuyo (IMBECU), Technology and Scientific Center (CCT)-National Research Council of Argentina (CONICET)
Mendoza
Argentina


Glenda Nicioli da Silva
Department of Oncology
The Affiliated Hospital of Luzhou Medical College
Luzhou Medical College
Luzhou
China


Sibel Mete
Departamento de Análises Clínicas – Escola de Farmácia
Universidade Federal de Ouro Preto – UFOP
Ouro Preto /MG
Brazil


Kinsie Arnst
Department of Pharmaceutical Sciences, College of Pharmacy
The University of Tennessee Health Science Center
Memphis, TN 38163
USA


Robert C. Jackson
Pharmacometrics Ltd
Cambridge
UK


Sayuri Sato
Department of Skin Oncology/Dermatology, Comprehensive Cancer Center
Saitama Medical University International Medical Center
Saitama
Japan


Tomas Radivoyevitch
Department of Quantitative Health Sciences
Cleveland Clinic, Cleveland
Ohio
USA


Ugir Hossain Sk
Natural Product Chemistry and Process Development Division
Institute of Himalayan Bioresource Technology
Palampur, H.P. 176 061
India


Wei Li
Department of Pharmaceutical Sciences, College of Pharmacy
The University of Tennessee Health Science Center
Memphis, TN 38163
USA


Yasuhiro Nakamura
Department of Skin Oncology/Dermatology, Comprehensive Cancer Center
Saitama Medical University International Medical Center
Saitama
Japan


Yukiko Teramoto
Department of Skin Oncology/Dermatology, Comprehensive Cancer Center
Saitama Medical University International Medical Center
Saitama
Japan




Advertisement

Adaptive Designs in Clinical Trials


Webmaster Contact: info@benthamscience.org Copyright © 2017 Bentham Science